In this study, multimodal ultrasound imaging combined with clinicopathological information could be effectively used to predict HER2‐low breast cancer, providing valuable imaging‐based evidence for clinical diagnosis, treatment, and prognosis assessment. This evidence concerns the gene ERBB2 and breast cancer.